EL7.AI
StocksMedium•20 October 2026•
4 min read

Inovio Announces $61,750,789 Damages Award Against Suppliers, Warns of Collection Difficulties

Key Facts

1The judgment includes damages of $61,750,789 and fees and costs of $18,665,312.
2Cash, cash equivalents and short-term investments totaled $36.7 million as of June 30, 2026.
3Operating expenses fell to $18.6 million for the three months ended June 30, 2026, compared with $23.1 million for the same period in 2025.
4Inovio expects the defendants' financial condition to hinder collection of some or all of the amount awarded.
5The U.S. Food and Drug Administration set October 30, 2026, as the target review date for the licensing application for the company's treatment for recurrent respiratory papillomatosis in adults.

Inovio Pharmaceuticals said in a statement issued in October 2026 that it had obtained a judgment in its favor in litigation against VGXI and GeneOne Life Science. The judgment includes damages of $61,750,789, according to the statement distributed through PR Newswire. It also includes $18,665,312 in fees and costs, which Inovio reported separately from the damages awarded. The announcement came with a warning that the defendants' financial condition would likely hinder collection of some or all of the amount. The judgment stems from a dispute over a supply agreement and a request to transfer manufacturing methods using the supplier's technology, according to the company's original disclosure of the lawsuit.

Inovio filed the lawsuit on June 3, 2020, according to its filing with the U.S. Securities and Exchange Commission at the outset of the dispute. Its original request sought to compel the two parties to facilitate the transfer of manufacturing methods under their existing supply agreement. The requested transfer involved the use of VGXI's technology, as the company described the scope of its request in that filing. VGXI was a wholly owned subsidiary of GeneOne Life Science, according to an earlier Inovio statement on expanding manufacturing. The subsidiary served as a contract manufacturer for Inovio, providing supplies for early clinical trials, a role that linked the parties before their dispute moved to court.

During the early stages of the case, Inovio sought a preliminary injunction in June 2020, but the request was denied, according to its SEC filing. Counterclaims disclosed by the company included allegations of trade secret misappropriation and unjust enrichment, claims made by parties to the dispute. In its filing for the period ended June 30, 2026, the company said the court had scheduled a trial to begin on October 13, 2026, with an expected duration of 7 days. In its statement announcing the judgment, however, it warned that post-trial motions or an appeal could affect the ruling. It said the judgment could be "reduced, vacated or otherwise modified," leaving the legal outcome subject to change.

On liquidity, Inovio had $36.7 million in cash, cash equivalents and short-term investments as of June 30, 2026, according to its quarterly SEC filing. That balance combines the cash, cash equivalents and short-term investments the company included in its reported figure at the end of the period. In its quarterly earnings statement, Inovio also disclosed net proceeds of approximately $18.3 million from a stock offering. It said the proceeds were after deducting underwriting discounts, commissions and offering expenses, according to the earnings statement published on its investor relations website. As for the amounts awarded, the company tied the prospects for collection to the defendants' financial condition, warning of obstacles that could affect the entire amount.

Inovio reported a decline in operating expenses for the three months ended June 30, 2026, according to its quarterly earnings statement. Those expenses totaled $18.6 million during the period, compared with $23.1 million in the corresponding months of 2025. The company's comparison covers operating expenses for the same quarterly period in both years, according to the earnings statement distributed through PR Newswire. The spending figure relates to the quarter ended in June, while the judgment was announced in October 2026. Alongside damages, the judgment includes a separate award for fees and costs, while Inovio remains exposed to the possibility that it may be unable to collect some or all of the amounts awarded.

Alongside the litigation, Inovio is awaiting a regulatory milestone for the licensing application for its treatment for recurrent respiratory papillomatosis in adults. The company said in its quarterly filing that the U.S. Food and Drug Administration had set a target date for reviewing the application. The application concerns the treatment the company is developing for the disease in adults, according to its SEC filing. On the legal front, the judgment remains subject to reduction, reversal or modification through post-trial motions or an appeal, as the company warned in its statement. The next regulatory milestone specified in Inovio's filing is the target review date for the licensing application on October 30, 2026.